MELBOURNE, Australia, Nov. 15, 2011 /PRNewswire/ -- Australian based brokerage firm Lodge Group has released a positive research note on NASDAQ and ASX listed Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) following an update with management on the roll-out of its lead molecular diagnostic cancer test in the US.
According to Lodge, the Company's lead product BREVAGen™, a predictive risk assessment tool for assessing women's risk of developing breast cancer, is demonstrating early success within its sales cycle in the US.
Importantly, the key drivers underpinning the future success of BREVAGen as a standard tool in assessing women's risk of developing breast cancer are being met.
Lodge believes Genetic Technologies has US management in place capable of delivering on the Company's molecular diagnostics strategy in North America, as well as scaling the normal learning curve associated with any new product launch.
Lodge noted key success factors in the BREVAGen roll-out include: implementation in six of the eight initial launch territories with plans for expansion, overall product receptiveness by target audience (obstetricians and gynecologists), and utilization of BREVAGen test results to gain insurance reimbursement for MRI breast exams.
Lodge Partners predicts increased market opportunity and acceptance for BREVAGen in their US Management Research Update report (available upon request) and has a 12 Month Price Target of AUD0.57 with an implied return of 320%.
thanks for the post Einstock. If you read their research report from a few months back you can see it is very thorough. The company is doing what it is supposed to do and the share price will follow.
there is einstock again!!! where the hell have you been man?. notice hes been missing???booking his profits from his shorts, when he needs another small spike to initiate a new short position he magically appears and convinces you tools to buy back in. what a buch of morons.